Healthcare systems are implementing precision medicine programs. They view their precision medicine programs as critical to providing the best patient care as well as to remaining competitive in the market. However, they face practical challenges, including empowering physicians with education on the value of molecular testing; access to high-quality, patient-specific interpretation of molecular diagnostic test results; and improving patient access to drugs, including through clinical trials.
This panel will discuss:
Anna B. Berry, MD, Scientific Director of Personalized Medicine, Swedish Cancer Institute & Medical Director of Molecular Diagnostics, CellNetix Pathology and Laboratories
Timothy L. Cannon, MD, Medical Oncologist and Clinical Director, Molecular Tumor Board and Personalized Medicine Initiative, Inova Schar Cancer Institute
Brad Perkins, MD, Chief Medical Officer, Human Longevity, Inc.
MODERATOR: Jennifer Levin Carter, MD, MPH, Chief Medical Officer and Founder, N-of-One